secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001104659-23-092871
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in cholangiocarcinoma
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation to NXP800 for cholangiocarcinoma.
- NXP800 is an oral small molecule targeting ARID1a-mutated cancers.
- Phase 1b trial ongoing in ARID1a-mutated ovarian carcinoma; cholangiocarcinoma expansion planned.
- CEO Ron Bentsur cites unmet medical need in cholangiocarcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923092871/0001104659-23-092871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923092871/tm2323981d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-092871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer